Literature DB >> 19578073

Proteasome inhibitors and cardiac cell growth.

Nadia Hedhli1, Christophe Depre.   

Abstract

Activation of the ubiquitin-proteasome system has been described in different models of cardiac hypertrophy. Cardiac cell growth in response to pressure or volume overload, as well as physiological adaptive hypertrophy, is accompanied by an increase in protein ubiquitination, proteasome subunit expression, and proteasome activity. Importantly, an inhibition of proteasome activity prevents and reverses cardiac hypertrophy and remodelling in vivo. The focus of this review is to provide an update about the mechanisms by which proteasome inhibitors affect cardiac cell growth in adaptive and maladaptive models of cardiac hypertrophy. In the first part, we summarize how the proteasome affects both proteolysis and protein synthesis in a context of cardiac cell growth. In the second part, we show how proteasome inhibition can prevent and reverse cardiac hypertrophy and remodelling in response to different conditions of overload.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578073      PMCID: PMC2797448          DOI: 10.1093/cvr/cvp226

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  98 in total

Review 1.  The ubiquitin-proteasome system in cardiac physiology and pathology.

Authors:  Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-02-24       Impact factor: 4.733

2.  Potential roles for ubiquitin and the proteasome during ribosome biogenesis.

Authors:  Diana A Stavreva; Miyuki Kawasaki; Miroslav Dundr; Karel Koberna; Waltraud G Müller; Teruko Tsujimura-Takahashi; Wataru Komatsu; Toshiya Hayano; Toshiaki Isobe; Ivan Raska; Tom Misteli; Nobuhiro Takahashi; James G McNally
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.

Authors:  Alexei F Kisselev; Alice Callard; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2006-02-02       Impact factor: 5.157

4.  H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart.

Authors:  Christophe Depre; Li Wang; Xiangzhen Sui; Hongyu Qiu; Chull Hong; Nadia Hedhli; Audrey Ginion; Amy Shah; Michel Pelat; Luc Bertrand; Thomas Wagner; Vinciane Gaussin; Stephen F Vatner
Journal:  Circ Res       Date:  2005-12-22       Impact factor: 17.367

5.  Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation.

Authors:  Mark J Post; Kaori Sato; Masahiro Murakami; Jialin Bao; Daniela Tirziu; Justin D Pearlman; Michael Simons
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-10-27       Impact factor: 3.619

6.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

Authors:  Esther A Obeng; Louise M Carlson; Delia M Gutman; William J Harrington; Kelvin P Lee; Lawrence H Boise
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

7.  Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload.

Authors:  Seiichi Oyadomari; Chi Yun; Edward A Fisher; Nicola Kreglinger; Gert Kreibich; Miho Oyadomari; Heather P Harding; Alan G Goodman; Hanna Harant; Jennifer L Garrison; Jack Taunton; Michael G Katze; David Ron
Journal:  Cell       Date:  2006-08-25       Impact factor: 41.582

8.  Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice.

Authors:  Osamu Tsukamoto; Tetsuo Minamino; Ken-ichiro Okada; Yasunori Shintani; Seiji Takashima; Hisakazu Kato; Yulin Liao; Hidetoshi Okazaki; Mitsutoshi Asai; Akio Hirata; Masashi Fujita; Yoshihiro Asano; Satoru Yamazaki; Hiroshi Asanuma; Masatsugu Hori; Masafumi Kitakaze
Journal:  Biochem Biophys Res Commun       Date:  2005-12-28       Impact factor: 3.575

9.  Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.

Authors:  Li Zhang; Zheng Gang Zhang; Xianshuang Liu; Ann Hozeska; Nancy Stagliano; William Riordan; Mei Lu; Michael Chopp
Journal:  Thromb Haemost       Date:  2006-01       Impact factor: 5.249

10.  Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.

Authors:  Jens Voortman; Giuseppe Giaccone
Journal:  BMC Cancer       Date:  2006-05-11       Impact factor: 4.430

View more
  25 in total

1.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Authors:  Saskia Schlossarek; Friederike Schuermann; Birgit Geertz; Giulia Mearini; Thomas Eschenhagen; Lucie Carrier
Journal:  J Muscle Res Cell Motil       Date:  2011-11-11       Impact factor: 2.698

Review 2.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

3.  Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure.

Authors:  Viswanathan Rajagopalan; Mingming Zhao; Sushma Reddy; Giovanni Fajardo; Xuejun Wang; Shannamar Dewey; Aldrin V Gomes; Daniel Bernstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-31       Impact factor: 4.733

Review 4.  Cardiac metabolism in heart failure: implications beyond ATP production.

Authors:  Torsten Doenst; Tien Dung Nguyen; E Dale Abel
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 5.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

6.  Ubiquitin, a novel paracrine messenger of cardiac cell survival.

Authors:  Dan Li; Christophe Depre
Journal:  Cardiovasc Res       Date:  2010-01-25       Impact factor: 10.787

Review 7.  The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.

Authors:  Lucie Carrier; Saskia Schlossarek; Monte S Willis; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2009-07-17       Impact factor: 10.787

8.  Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.

Authors:  Xuejun Wang
Journal:  Eur J Heart Fail       Date:  2013-05-02       Impact factor: 15.534

9.  Myosin light chain phosphorylation is critical for adaptation to cardiac stress.

Authors:  Sonisha A Warren; Laura E Briggs; Huadong Zeng; Joyce Chuang; Eileen I Chang; Ryota Terada; Moyi Li; Maurice S Swanson; Stewart H Lecker; Monte S Willis; Francis G Spinale; Julie Maupin-Furlowe; Julie R McMullen; Richard L Moss; Hideko Kasahara
Journal:  Circulation       Date:  2012-10-24       Impact factor: 29.690

10.  Clarifying the cardiac proteasome paradox: protein quality control.

Authors:  Christopher C Glembotski
Journal:  Circ Res       Date:  2012-08-17       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.